Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with …
DJ Sargent, CH Köhne, HK Sanoff, BM Bot… - Journal of Clinical …, 2009 - ascopubs.org
Purpose Performance status (PS) is a prognostic factor in patients with metastatic colorectal
cancer. Clinical trials typically enroll less than 10% of patients with a PS of 2 (PS2); thus, the …
cancer. Clinical trials typically enroll less than 10% of patients with a PS of 2 (PS2); thus, the …
Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials …
Q Shi, A De Gramont, A Grothey, J Zalcberg… - Journal of Clinical …, 2015 - ascopubs.org
Purpose Progression-free survival (PFS) has previously been established as a surrogate for
overall survival (OS) for first-line metastatic colorectal cancer (mCRC). Because mCRC …
overall survival (OS) for first-line metastatic colorectal cancer (mCRC). Because mCRC …
Overall survival in phase 3 clinical trials and the Surveillance, Epidemiology, and End Results database in patients with metastatic colorectal cancer, 1986-2016: a …
C Shen, D Tannenbaum, R Horn, J Rogers… - JAMA network …, 2022 - jamanetwork.com
Importance Phase 3 trials for patients with metastatic colorectal cancer (mCRC) have been
conducted with varying designs and often with surrogate end points for overall survival (OS) …
conducted with varying designs and often with surrogate end points for overall survival (OS) …
Colorectal cancer survival gains and novel treatment regimens: a systematic review and analysis
Importance The past 2 decades have witnessed progress in the management of metastatic
colorectal cancer (mCRC) with more effective agents and better surgical, medical, and …
colorectal cancer (mCRC) with more effective agents and better surgical, medical, and …
Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma
C Louvet, A de Gramont, C Tournigand… - … Journal of the …, 2001 - Wiley Online Library
BACKGROUND All endpoint measures currently used to evaluate chemotherapeutic
treatment benefit in clinical trials of patients with metastatic colorectal carcinoma (MCRC) …
treatment benefit in clinical trials of patients with metastatic colorectal carcinoma (MCRC) …
Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line …
PA Tang, SM Bentzen, EX Chen, LL Siu - Journal of Clinical Oncology, 2007 - ascopubs.org
Purpose Our aims were to determine the correlations between progression-free survival
(PFS), time to progression (TTP), and response rate (RR) with overall survival (OS) in the …
(PFS), time to progression (TTP), and response rate (RR) with overall survival (OS) in the …
The effects of palliative chemotherapy in metastatic colorectal cancer patients with an ECOG performance status of 3 and 4
MC Teixeira, DF Marques, AC Ferrari, MFS Alves… - Clinical colorectal …, 2015 - Elsevier
Background Although chemotherapy is standard for patients with mCRC and ECOG PS of
0/1, the real benefit for patients with ECOG PS> 2 remains uncertain, because they are …
0/1, the real benefit for patients with ECOG PS> 2 remains uncertain, because they are …
Evaluation of progression-free survival as a surrogate endpoint for survival in chemotherapy and targeted agent metastatic colorectal cancer trials
R Sidhu, A Rong, S Dahlberg - Clinical Cancer Research, 2013 - AACR
Pooled analyses of chemotherapy trials in metastatic colorectal cancer (mCRC) have
suggested that progression-free survival (PFS) is a surrogate endpoint for overall survival …
suggested that progression-free survival (PFS) is a surrogate endpoint for overall survival …
[HTML][HTML] Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer
F Petrelli, S Barni - Annals of oncology, 2013 - Elsevier
Background Polychemotherapy and biological drugs have increased therapeutic options
and outcomes of advanced colorectal cancer (CRC). We examined the relation between …
and outcomes of advanced colorectal cancer (CRC). We examined the relation between …
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107
A Grothey, EE Hedrick, RD Mass, S Sarkar… - Journal of Clinical …, 2008 - ascopubs.org
Purpose In the phase III study AVF2107g, bevacizumab (BV) demonstrated a survival benefit
when added to irinotecan, fluorouracil, and leucovorin (IFL) in first-line metastatic colorectal …
when added to irinotecan, fluorouracil, and leucovorin (IFL) in first-line metastatic colorectal …